Literature DB >> 12036270

Agreement between general practice prescription data and self-reported use of hormone replacement therapy and treatment for various illnesses.

E Banks1, V Beral, R Cameron, A Hogg, N Langley, I Barnes, D Bull, J Elliman, C L Harris.   

Abstract

BACKGROUND: Epidemiological studies of the effects of hormone replacement therapy (HRT) often rely on exposure data and information on past health from self-administered questionnaires. The accuracy with which women report current use of HRT and the specific preparation in use is not known. This study aims to compare aspects of self-reported use of HRT and treatment for various conditions with data from general practice prescription records.
METHODS: Reported questionnaire data on use of HRT were compared with those on the general practice prescription record for 570 women participating in the Million Women Study from two general practices in the UK.
RESULTS: There was excellent agreement between data from the self-administered questionnaire and the prescription record: 96% agreement (kappa = 0.91) for current use of HRT, 95% agreement (kappa = 0.90) for any use of HRT during the period covered by the prescription record, and 97% agreement (kappa = 0.95) among current users for whether the HRT preparation contained oestrogen alone, combined oestrogen/progestogen, or some other constituents. Among former HRT users who provided questionnaire information on the preparation they used most recently, there was 69% agreement on the proprietary preparation used and 97% agreement (kappa = 0.93) on the hormonal constituents used. Agreement between reported treatment for various conditions and the presence of a prescription appropriate for that condition ranged from 89-99% (kappa 0.53-0.92), and was highest for thyroid disease and asthma.
CONCLUSION: Important aspects of use of HRT, such as type of preparation currently being used, are reported very reliably by women completing a self-administered questionnaire.

Entities:  

Mesh:

Year:  2001        PMID: 12036270     DOI: 10.1080/13595220152601837

Source DB:  PubMed          Journal:  J Epidemiol Biostat        ISSN: 1359-5229


  28 in total

1.  Could recent decreases in breast cancer incidence really be due to lower HRT use? Trends in attributable risk for modifiable breast cancer risk factors in Canadian women.

Authors:  C Ineke Neutel; Howard Morrison
Journal:  Can J Public Health       Date:  2010 Sep-Oct

2.  Hormone therapy and fatal breast cancer.

Authors:  Sandra A Norman; Anita L Weber; A Russell Localio; Polly A Marchbanks; Giske Ursin; Brian L Strom; Linda K Weiss; Ronald T Burkman; Leslie Bernstein; Dennis M Deapen; Suzanne G Folger; Michael S Simon; Marion R Nadel
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-05       Impact factor: 2.890

3.  Influence of personal characteristics of individual women on sensitivity and specificity of mammography in the Million Women Study: cohort study.

Authors:  Emily Banks; Gillian Reeves; Valerie Beral; Diana Bull; Barbara Crossley; Moya Simmonds; Elizabeth Hilton; Stephen Bailey; Nigel Barrett; Peter Briers; Ruth English; Alan Jackson; Elizabeth Kutt; Janet Lavelle; Linda Rockall; Matthew G Wallis; Mary Wilson; Julietta Patnick
Journal:  BMJ       Date:  2004-08-28

4.  Postmenopausal hormone replacement therapy and risk of acute pancreatitis: a prospective cohort study.

Authors:  Viktor Oskarsson; Nicola Orsini; Omid Sadr-Azodi; Alicja Wolk
Journal:  CMAJ       Date:  2014-01-27       Impact factor: 8.262

5.  Postmenopausal Female Hormone Use and Estrogen Receptor-Positive and -Negative Breast Cancer in African American Women.

Authors:  Lynn Rosenberg; Traci N Bethea; Emma Viscidi; Chi-Chen Hong; Melissa A Troester; Elisa V Bandera; Christopher A Haiman; Laurence N Kolonel; Andrew F Olshan; Christine B Ambrosone; Julie R Palmer
Journal:  J Natl Cancer Inst       Date:  2015-11-26       Impact factor: 13.506

6.  Gene-environment interactions in 7610 women with breast cancer: prospective evidence from the Million Women Study.

Authors:  Ruth C Travis; Gillian K Reeves; Jane Green; Diana Bull; Sarah J Tipper; Krys Baker; Valerie Beral; Richard Peto; John Bell; Diana Zelenika; Mark Lathrop
Journal:  Lancet       Date:  2010-06-03       Impact factor: 79.321

7.  Recent trends in hormone therapy utilization and breast cancer incidence rates in the high incidence population of Marin County, California.

Authors:  Rochelle R Ereman; Lee Ann Prebil; Mary Mockus; Kathy Koblick; Fern Orenstein; Christopher Benz; Christina A Clarke
Journal:  BMC Public Health       Date:  2010-04-30       Impact factor: 3.295

8.  Postmenopausal hormone therapy and non-Hodgkin lymphoma: a pooled analysis of InterLymph case-control studies.

Authors:  E V Kane; L Bernstein; P M Bracci; J R Cerhan; L Costas; L Dal Maso; E A Holly; C La Vecchia; K Matsuo; S Sanjose; J J Spinelli; S S Wang; Y Zhang; T Zheng; E Roman; A Kricker
Journal:  Ann Oncol       Date:  2012-09-11       Impact factor: 32.976

9.  A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999-2010.

Authors:  Brian L Sprague; Amy Trentham-Dietz; Kathleen A Cronin
Journal:  Obstet Gynecol       Date:  2012-09       Impact factor: 7.661

10.  Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks?

Authors:  Agnès Fournier; Sylvie Mesrine; Marie-Christine Boutron-Ruault; Françoise Clavel-Chapelon
Journal:  J Clin Oncol       Date:  2009-09-14       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.